Erenumab For Treatment of Hemicrania Continua

Mayo Clinic

Status and phase

Terminated

Phase 2

Conditions

Hemicrania Continua

Treatments

Drug: Erenumab

Study type

Interventional

Funder types

Other

Identifiers

NCT04303845

19-007088

Details and patient eligibility

About

This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.

Enrollment

2 patients

Sex

All

Ages

18 to 66 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Adults over the age of 18-66
At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1
Previous or current complete response to indomethacin
Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment

Exclusion Criteria

Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week
Pregnant or lactating subjects
Use of barbiturate or opioid >6 days per month; history of chronic migraine
History of previous trigeminal-autonomic cephalalgia
History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy)
History of cranial nerve/rhizolysis
Botulinumtoxin injection with previous 4 months
Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase